INTRODUCING THE AMR INDUSTRY ALLIANCE

THE LARGEST PRIVATE SECTOR COALITION TO PROVIDE SUSTAINABLE SOLUTIONS TO CURB ANTIMICROBIAL RESISTANCE

amrindustryalliance.org
Antimicrobial resistance (AMR) is recognized as one of the most serious health concerns worldwide. The WHO, G7, G20 and many world leaders have acknowledged the growing dangers AMR presents and have called for concerted action from all relevant actors to work on solutions and their implementation.

The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotechnology, diagnostics, generics and research-based pharmaceutical companies and associations joining forces. It facilitates collaboration, reports on industry’s contribution to the fight against AMR and engages with external stakeholders.

**OUR VISION**

**CONTRIBUTING SUSTAINABLE SOLUTIONS TO CURB ANTIMICROBIAL RESISTANCE BY CREATING BROAD INDUSTRY MOMENTUM AND FACILITATING COLLABORATION BETWEEN THE PUBLIC AND PRIVATE SECTORS**
AMR INDUSTRY ALLIANCE

AMR is recognized as one of the most serious health concerns worldwide. The WHO, G7, G20 and many world leaders have acknowledged the growing dangers AMR presents. It threatens the attainment of the Sustainable Development Goals (SDGs).

In 2016, the United Nations called for concerted action from governments and various sectors to address the implications of antimicrobial resistance in a comprehensive manner, and implement strategies at national level. The AMR Industry Alliance is a unique venture, a coalition of the life sciences industry, in response to the call for action. It supports proactive action by companies and enables collaboration.
HOW THE ALLIANCE SUPPORTS MEMBERS

A NETWORK FOR COMPANY COLLABORATION & SHARING EXPERTISE

A PLATFORM FOR EXTERNAL STAKEHOLDER ENGAGEMENT & ADVOCACY

A COMMUNICATIONS TOOL & VISIBILITY

GUIDED BY KEY PRINCIPLES

INCLUSIVITY
The Alliance welcomes all sectors of the life sciences industry and supports them at different levels of maturity and development in their engagement to combat AMR.

COLLABORATION
The Alliance is committed to assessing its progress, sharing its successes and challenges, and learnings.

ACCOUNTABILITY
The Alliance will regularly report on the progress of its members. The collective actions of the Alliance form a measure of the industry’s success.
A NETWORK FOR COMPANY COLLABORATION & SHARING EXPERTISE

Within the life sciences industry, the Alliance provides a platform enabling members to collaborate and share information by:

A. INFORMATION SHARING
We monitor global AMR developments to help you identify risks and opportunities.

B. PROVIDING A PLATFORM FOR INDUSTRY EXPERTISE
Through our working groups, we foster industry thought leadership and provide insights into key political, technical and regulatory aspects of AMR.

C. SOURCE OF NEW INDUSTRY INSIGHTS & SOLUTIONS
We collect company data to develop an industry-wide overview of progress in the fight against AMR.

The Alliance hosts working groups to help its members engage on topics such as:

- RESEARCH & SCIENCE
- APPROPRIATE USE
- ACCESS
- ENVIRONMENT

PROGRESS REPORTS
The biennial production of a progress report as a way to share practical examples and serve as a foundation for engagement with external stakeholders.
A PLATFORM FOR EXTERNAL STAKEHOLDER ENGAGEMENT & ADVOCACY

The Alliance is a convener and focal point for key external stakeholders through:

<table>
<thead>
<tr>
<th>A. SHAPING THE DIRECTION OF THE GLOBAL HEALTH DIALOGUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Alliance has provided a comprehensive set of comments to all IACG sub-groups, and engages with key multilateral forums from the WHO, G7 and G20.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. CONVENING MEETINGS WITH EXPERTS TO SHARE PROGRESS &amp; SEEK GUIDANCE &amp; FEEDBACK</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Alliance convenes meetings with its external advisory group composed of:</td>
</tr>
<tr>
<td>- ACADEMIA</td>
</tr>
<tr>
<td>- GOVERNMENTS</td>
</tr>
<tr>
<td>- CIVIL SOCIETY</td>
</tr>
<tr>
<td>- NGOs</td>
</tr>
<tr>
<td>- INTERNATIONAL ORGANIZATIONS</td>
</tr>
<tr>
<td>- AND MORE...</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C. REPRESENTING INDUSTRY IN HIGH-LEVEL POLITICAL FORA AND AMONG KEY OPINION LEADERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Alliance Chair actively engages at the highest levels of global health discussions on AMR to provide the life sciences industry perspective.</td>
</tr>
</tbody>
</table>
## A COMMUNICATIONS TOOL

The Alliance supports unified communication and enables participation and coverage:

### A. PROVIDING AN ONLINE PLATFORM TO COMMUNICATE MEMBERS ACTIVITIES

- On its dedicated website and through media channels, the Alliance provides visibility to company specific initiatives with the publication of case studies.
- Dedicated communications workstream comprised of representatives of the four sub-sectors.

### B. ORGANISING MEDIA COVERAGE & FACILITATING PARTICIPATION IN KEY EVENTS

- The Alliance organises press conferences, interviews and briefings.
- The Alliance provides speaking opportunities and supports member preparation and participation.

### C. RECOGNITION BY KEY OPINION LEADERS

We ensure that the role of the industry is recognized and that companies have a seat at the table.

Prof. Dame Sally Davies, Co-convener and Member of the United Nations Interagency Coordination Group on Antimicrobial Resistance (UN IACG):

"The private sector has a crucial role to play in addressing drug-resistant superbugs globally."

Dr. Jeremy Farrar, Director, Wellcome Trust:

"Industry’s role in addressing drug-resistant infections is critical and it is heartening to see many companies stepping-up to help tackle this global health threat."
CASE STUDY N°1: POSITIONING THE LIFE-SCIENCES INDUSTRY AS A SOLUTION PROVIDER AND PARTNER

INCREASED REACH AND IMPACT

GROWING MENTIONS IN KEY GLOBAL REPORTS

The Alliance has been consistently referenced in key global AMR reports contributing to position the life-sciences industry as an indispensable partner to find sustainable solutions.

- 25+ References in key global AMR reports
- Interagency Coordination Group on Antimicrobial Resistance
- OECD
- DRIVE
- World Health Organization

TOWARDS A MORE SYSTEMATIC REPRESENTATION OF THE INDUSTRY IN HIGH-LEVEL POLITICAL FORA

- Secured a seat at the table
- Present industry's perspective in AMR global health discussions
- Provide technical expertise
- Dialogue with leading global experts
- Ensure the Alliance is part of the solution
- Facilitate stakeholders alignment

RISING MEDIA TRACTION AND ACKNOWLEDGEMENT

- The Alliance has quickly become a credible voice for the industry in the media.
- Respond to media requests on behalf of the Alliance members

INCREASING REACH, QUALITY OF COVERAGE, QUANTITY OF MEDIA

- Audiences of up to 79m
- BBC World Service
- The Guardian
- FT
- CNBC
- POLITICO
- Intellectual Property Watch
- Devex

The Alliance has quickly become a credible voice for the industry in the media.
### Case Study N°2: Advancing the Broader Life-Sciences Industry Progress through Proactive Engagement

**Driving Discussions on Antibiotic Manufacturing Discharge in the Environment**

<table>
<thead>
<tr>
<th>Development of Industry’s Own Solutions</th>
<th>Launched Pioneering Work</th>
<th>Established the Alliance as a Responsible Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Alliance helped leverage private sector’s expertise and developed a <strong>unified approach</strong> to help drive down manufacturing discharges.</td>
<td>The Alliance’s Common Antibiotic Manufacturing Framework and discharge targets list positioned members <strong>ahead of the curve in defining standards</strong> to minimize antibiotic manufacturing discharge in the environment.</td>
<td>By proactively engaging to reduce the potential AMR developing from manufacturing effluent, Alliance members demonstrated that the industry is part of the solution.</td>
</tr>
</tbody>
</table>

- **Shared & Analyzed Companies’ Data to Inform Industry’s Response**
  - Alliance members worked jointly to identify best practices
  - Published two guiding industry documents

- **The Alliance will leverage its pioneering work to advocate for the development of standards that are:**
  - Science-driven
  - Risk-based
  - Harmonized

---

**Alex Azar**, Secretary of Health and Human Services, US:

"The AMR Alliance, which represents more than 100 pharmaceutical companies, agreed earlier in 2018 on a framework that promotes responsible antibiotic manufacturing."

---

**Joakim Larsson**, director of CARe, comments on the discharge targets:

"This is an important and very much needed initiative from industry, particularly as regulators world-wide have not yet stepped up to responsibility and applied legally binding discharge limits for antibiotics."
OUR STRUCTURE

A Secretariat serves the AMR Industry Alliance with the responsibility of implementing the activities endorsed by the Board.

GOVERNED BY A BOARD OF MEMBERS

- Comprised of the four life sciences sub-sectors:
  - BIOTECHS
  - DIAGNOSTICS
  - GENERICS
  - R&D PHARMA

- Board meets in-person twice a year and connects regularly through teleconferences

- The Alliance is funded through membership fees

WORKING GROUPS DEDICATED TO THE KEY AREAS

JOIN THE ALLIANCE

Private sector companies are invited to join us.

REQUIREMENTS

- Agree to report on a series of metrics relevant to your business activities
- Consider participating in Working Groups and on the Board
- Nominate a principal contact

Full list of members at amrindustryalliance.org

CONTACT US

AMR Industry Alliance Secretariat
Chemin des Mines 9
P.O. Box 195
1211 Geneva 20
Switzerland

+41 22 338 32 00
info@amrindustryalliance.org
@AMRAlliance